NCT04895462 is a clinical trial in Ischemic Stroke, sponsored by Centre Hospitalier Universitaire Vaudois.

Who is sponsoring NCT04895462?

NCT04895462 is sponsored by Centre Hospitalier Universitaire Vaudois.

What condition does NCT04895462 study?

NCT04895462 studies Ischemic Stroke, Covid19.

Is NCT04895462 still recruiting?

NCT04895462 is currently completed. Last updated 8 March 2023.

Last reviewed 2023-03-08 · How we verify

NCT04895462

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Revascularization Treatment in Ischemic Stroke Patients With COVID-19

Completed Last updated 8 March 2023

What this trial tests

trial in Ischemic Stroke in 15,128 participants. Completed in 30 October 2021.

Timeline

30 April 2021

Primary endpoint
31 August 2021

30 October 2021

Quick facts

Lead sponsor	Centre Hospitalier Universitaire Vaudois
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15,128
Start date	30 April 2021
Primary completion	31 August 2021
Estimated completion	30 October 2021
Sites	1 location across Switzerland

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →
Covid19 — all drugs for Covid19 →

Sponsor

Centre Hospitalier Universitaire Vaudois

Who can join

18 and older, any sex, with Ischemic Stroke or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Case-series and cohort studies have shown the feasibility of reperfusion therapies in patients with ischemic stroke and COVID-19, but due to the absence of a contemporary control group of non-COVID-19 patients, small sample size or lack of long-term outcome assessment, concerns regarding safety and efficacy of these treatments remain to be clarified. Taking into account its limitations, some studies documented higher rates of endovascular treatment complications such as clot fragmentation with distal embolization and vessel re-oclusion, to be more difficult to achieve recanalization after endovascular treatment, and higher rates of any intracerebral hemmorhage. The investigators aim is to assess in a large, multicenter and international cohort, the safety and outcomes of acute reperfusion therapies in patients with ischemic stroke and COVID-19, by comparison with a contemporary control group of patients with ischemic stroke and without COVID-19 from the same centers.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.
Marto JP, Strambo D, Ntaios G, Nguyen TN, et al · · 2023 · cited 25× · PMID 36351814 · DOI 10.1212/wnl.0000000000201537
Effect of Asymptomatic and Symptomatic COVID-19 on Acute Ischemic Stroke Revascularization Outcomes.
Strambo D, Marto JP, Ntaios G, Nguyen TN, et al · · 2024 · cited 10× · PMID 38134260 · DOI 10.1161/strokeaha.123.043899
Sex differences in acute stroke metrics and outcome dependent on COVID status.
Mayer-Suess L, Marto JP, Strambo D, Ntaios G, et al · · 2024 · cited 2× · PMID 38288522 · DOI 10.1111/ene.16221
ESOC 2022 Abstract Book
· 2022

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Centre Hospitalier Universitaire Vaudois trials

Trials by the same sponsor.

NCT07427511 — SwissNeuroRehab - HDHI · NA · recruiting
NCT07263438 — Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a · Phase 2 · recruiting
NCT07139756 — Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension · not yet recruiting
NCT07109388 — Comparison of Pericapsular Nerve Group (PENG) Block With a Combined Femoral, Sciatic, Lateral Femoral Cutaneous Nerve Bl · NA · not yet recruiting
NCT07268378 — Supervision of Clinicians in Oncology by Psycho-oncologists : Evaluation · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04895462 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Vaudois
Last refreshed: 8 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04895462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing